HEALTHCARE CAPITAL FORUM
Industry Investor Panel
Friday, November 7th, 2014
8:00 am Breakfast & Networking
8:45 am Introduction
8:50 am Introduction of Presenting Companies
9:45 am Investor Panel
10:45 am Concluding Remarks
68 S. Service Road, Melville, NY
(Meeting Auditorium below Lobby Level)
LICA Members - No Charge - JOIN NOW!
Non-Members - $65
The capital forum provides an opportunity to meet capital providers and businesses seeking capital, as well as to hear a panel of industry experts discuss financing alternatives for health care companies.
Affiliated with Stony Brook University, AdMedDev provides advanced sensors and wireless medical electronic devices used in tracking and analyzing data associated with medical specimens.
Produces the SightSaver™, a patented FDA-approved device for eliciting visual evoked physiological responses. There are over 2 million operations performed annually that can cause post-operative visual loss. SightSaver provides a hygienic, safe, comfortable, and effective alternative to current solutions.
As creator of four venture backed medical device companies, PAXmed is a vehicle to accelerate the development of device start-ups utilizing capital efficiency strategies to enhance value creation and return on invested capital.
Develops powerful microbiome-based therapeutics to cure and prevent infection caused by the depletion of symbiotic microbes due to antibiotics, addressing a $4.8 billion market.
Based at Stony Brook University’s Center for Biotechnology, Traverse Biosciences is commercializing a proprietary pipeline of drug candidates to treat inflammatory diseases and age‐related conditions affecting humans and companion animals. FDA approval is being sought for a lead drug intended to prevent canine periodontal disease.
Industry Investor Panel
David Calone, Jove Equity Partners
David Calone is the CEO of Jove Equity Partners, LLC, a firm that manages private equity and venture capital investments. He serves on the Board of Directors of eight privately-held companies. Mr. Calone previously served as a federal prosecutor in the U.S. Department of Justice's Honors Program where he received a 2003 Attorney General's Award for his work in fighting terrorism-related and corporate international crime. Mr. Calone also served as a Special Assistant Attorney General in the New York State Attorney General's Office and was an associate at Paul Weiss Rifkind Wharton & Garrison in New York. He has a degree in economics from Princeton University and received a J.D. from Harvard Law School.
William Ho, AlephPoint Capital
William Ho founded AlephPoint Capital, a healthcare equity hedge fund, in 2014. Prior to AlephPoint, in 2010 he joined New Leaf Venture Partners, a leading healthcare venture capital fund, to launch the firm's efforts in the public equities markets. Previously, he has held senior positions on a derivatives trading desk of ICAP plc, as an equity research analyst covering the biotechnology industry at Bank of America, and at Piper Jaffray & Co. covering the biotechnology and life-sciences tools sectors. Earlier in his career, Mr. Ho held an operational role at CuraGen Corporation, a genomics biotechnology company, where he twice restructured the company, and was an associate in the healthcare investment banking group at SG Cowen. He holds an MBA from the University of Notre Dame and a BS in Biochemistry from McMaster University in Canada.
Antony E. Pfaffle, M.D., CorMedix Inc.
Dr. Antony E. Pfaffle is Chief Scientific Officer of CoreMedix, Inc., a speciality pharmaceutical company. Dr. Pfaffle is the Advisory Chief Medical Officer at ParagonRx, which creates pharmaceutical safe programs. He has been the Director of Healthcare Research at Bearing Circle Capital, L.P., an investment fund, since May 2007. He was a Managing Director at Paramount BioCapital, Inc. and Senior Vice-President of Business Development at Paramount BioSciences, LLC from December 2005 to May 2007. Dr. Pfaffle was a Principal and Founder of Black Diamond Research, an investment research company, from July 2001 to December 2005. He is an internist who practiced nephrology at New York Hospital, Lenox Hill and Memorial Sloan-Kettering, and received his M.D. degree from New York Medical College in 1989.
Clayton Besch III, Empire State Development
Clayton Besch is Director of the Small Business Technology Investment Fund (SBTIF) at Empire State Development. The SBTIF provides early stage high-tech companies throughout New York with a potential source of venture capital to promote new job creation and economic growth. Previously, Mr. Besch worked at the New York State (NYS) Department of Economic Development, where he ran the Asian Office, introducing NYS companies to sales opportunities in Japan and Korea and introducing Japanese companies to strategic opportunities in NYS. He also spent a number of years at SOFTBANK INC. as development advisor, working with SOFTBANK's worldwide VC network, including GrandBanks Capital, Mobius Ventures and SOFTBANK Capital Partners. Mr. Besch is currently an observer on the boards of e2e Materials and Float Tech Inc. Mr. Besch holds a BS from Hamilton College in NYS, an MS from Nagasaki University and a PhD from Tokyo University.